Find a Doctor
Robert Galamaga, DO, MS, is a hematologist and medical oncologist with Barrow Oncology and the Head and Neck Cancer Program at Barrow Neurological Institute. He is board certified in internal medicine, hematology, and medical oncology by the American Board of Internal Medicine.
Dr. Galamaga’s expertise includes caring for patients with head and neck cancers, and advanced cancers that have metastasized to the brain or spine. Dr. Galamaga also has extensive training and experience in the treatment of hematologic malignancies. He is a member of the American Association of Blood Banks, the American Society of Clinical Oncology, the American Society of Hematology, and the American Telemedicine Association.
Dr. Galamaga earned his medical degree from the Lake Erie College of Osteopathic Medicine in Erie, Pennsylvania, and a Master of Science in Pharmacy Sciences from the University of Maryland in Rockville. He completed his residency in internal medicine at the University of Illinois at Urbana-Champaign. Additionally, Dr. Galamaga completed a fellowship in transfusion medicine and blood banking at the University of Illinois at Chicago, followed by a fellowship in hematology and oncology at Advocate Lutheran General Hospital in Park Ridge, Illinois.
Dr. Galamaga’s research interests include a focus on advances in precision medicine, which allow patients to benefit from highly targeted therapies. Dr. Galamaga has served as principal investigator on numerous clinical trials, which have focused on the use of novel agents and immunotherapy in the treatment of advanced malignancies. His approach to cancer treatment is informed by participation in clinical trials and early adoption of emerging therapies, which show promise in the field of hematology and medical oncology.
- MS, University of Maryland, Pharmacy Sciences, 2021
- Fellowship, Advocate Lutheran General Hospital, Hematology and Oncology, 2010-2013
- Fellowship, University of Illinois at Chicago, Transfusion Medicine and Blood Banking, 2008-2010
- Residency, University of Illinois at Urbana-Champaign, 2002-2005
- DO, Lake Erie College of Osteopathic Medicine, 2002
- BS, Tulane University, Cellular and Molecular Biology, 1996
- American Association of Blood Banks
- American Society of Clinical Oncology
- American Society of Hematology
- American Telemedicine Association
- Hope Colleague Award, City of Hope, 2023
- Phi Kappa Phi Honor Society, University of Maryland, 2021
- Scholarship Recipient, Great Debates & Updates in GI Malignancies Program 2020
- Patients’ Choice Award, Vitals.com, 2016-2018, 2020
- Compassionate Doctor Recognition, Vitals.com, 2016, 2018-2020
- On-Time Doctor Award, Vitals.com, 2014, 2016-2018, 2020
- Top Doctor Evanston, Healthtap.com, 2018
- Fellow Physician of the Year, Advocate Lutheran General Hospital, 2012
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Date: 01/2024
Authors: Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri, Rob Galamaga, Robert Galamaga
Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study
Date: 10/2023
Authors: Jonathan Q. Trinh, Cassaundra Acosta, Arti Easwar, Robert Galamaga, Alan Tan
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Date: 08/2021
Authors: Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N Symeonides, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M Burke, Gurjyot Doshi, Delphine Topart, Stephane Oudard, Hans Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I Quinn, Thomas Powles, Rob Galamaga, Robert Galamaga
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Date: 07/2021
Authors: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Rob Galamaga, Robert Galamaga
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Date: 04/2021
Authors: Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri, Rob Galamaga, Robert Galamaga
- English
- (602) 406-6387
- Fax: (602) 406-2931
Robert Galamaga, DO, MS, is a hematologist and medical oncologist with Barrow Oncology and the Head and Neck Cancer Program at Barrow Neurological Institute. He is board certified in internal medicine, hematology, and medical oncology by the American Board of Internal Medicine.
Dr. Galamaga’s expertise includes caring for patients with head and neck cancers, and advanced cancers that have metastasized to the brain or spine. Dr. Galamaga also has extensive training and experience in the treatment of hematologic malignancies. He is a member of the American Association of Blood Banks, the American Society of Clinical Oncology, the American Society of Hematology, and the American Telemedicine Association.
Dr. Galamaga earned his medical degree from the Lake Erie College of Osteopathic Medicine in Erie, Pennsylvania, and a Master of Science in Pharmacy Sciences from the University of Maryland in Rockville. He completed his residency in internal medicine at the University of Illinois at Urbana-Champaign. Additionally, Dr. Galamaga completed a fellowship in transfusion medicine and blood banking at the University of Illinois at Chicago, followed by a fellowship in hematology and oncology at Advocate Lutheran General Hospital in Park Ridge, Illinois.
Dr. Galamaga’s research interests include a focus on advances in precision medicine, which allow patients to benefit from highly targeted therapies. Dr. Galamaga has served as principal investigator on numerous clinical trials, which have focused on the use of novel agents and immunotherapy in the treatment of advanced malignancies. His approach to cancer treatment is informed by participation in clinical trials and early adoption of emerging therapies, which show promise in the field of hematology and medical oncology.
- (602) 406-6387
- Fax: (602) 406-2931
- MS, University of Maryland, Pharmacy Sciences, 2021
- Fellowship, Advocate Lutheran General Hospital, Hematology and Oncology, 2010-2013
- Fellowship, University of Illinois at Chicago, Transfusion Medicine and Blood Banking, 2008-2010
- Residency, University of Illinois at Urbana-Champaign, 2002-2005
- DO, Lake Erie College of Osteopathic Medicine, 2002
- BS, Tulane University, Cellular and Molecular Biology, 1996
- American Association of Blood Banks
- American Society of Clinical Oncology
- American Society of Hematology
- American Telemedicine Association
- Hope Colleague Award, City of Hope, 2023
- Phi Kappa Phi Honor Society, University of Maryland, 2021
- Scholarship Recipient, Great Debates & Updates in GI Malignancies Program 2020
- Patients’ Choice Award, Vitals.com, 2016-2018, 2020
- Compassionate Doctor Recognition, Vitals.com, 2016, 2018-2020
- On-Time Doctor Award, Vitals.com, 2014, 2016-2018, 2020
- Top Doctor Evanston, Healthtap.com, 2018
- Fellow Physician of the Year, Advocate Lutheran General Hospital, 2012
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Date: 01/2024
Authors: Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri, Rob Galamaga, Robert Galamaga
Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study
Date: 10/2023
Authors: Jonathan Q. Trinh, Cassaundra Acosta, Arti Easwar, Robert Galamaga, Alan Tan
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Date: 08/2021
Authors: Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N Symeonides, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M Burke, Gurjyot Doshi, Delphine Topart, Stephane Oudard, Hans Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I Quinn, Thomas Powles, Rob Galamaga, Robert Galamaga
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Date: 07/2021
Authors: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Rob Galamaga, Robert Galamaga
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Date: 04/2021
Authors: Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri, Rob Galamaga, Robert Galamaga
- English